LLY

1,010.33

+1.95%↑

JNJ

228.54

+0.2%↑

ABBV

214.5

+2.69%↑

UNH

391.82

+1.33%↑

AZN

185.21

+0.47%↑

LLY

1,010.33

+1.95%↑

JNJ

228.54

+0.2%↑

ABBV

214.5

+2.69%↑

UNH

391.82

+1.33%↑

AZN

185.21

+0.47%↑

LLY

1,010.33

+1.95%↑

JNJ

228.54

+0.2%↑

ABBV

214.5

+2.69%↑

UNH

391.82

+1.33%↑

AZN

185.21

+0.47%↑

LLY

1,010.33

+1.95%↑

JNJ

228.54

+0.2%↑

ABBV

214.5

+2.69%↑

UNH

391.82

+1.33%↑

AZN

185.21

+0.47%↑

LLY

1,010.33

+1.95%↑

JNJ

228.54

+0.2%↑

ABBV

214.5

+2.69%↑

UNH

391.82

+1.33%↑

AZN

185.21

+0.47%↑

Accueil・Liste d'Actions・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Ouvert

SecteurSoins de santé

2.1 -2.78

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.02

Max

2.19

Chiffres clés
By Trading Economics
Revenu	14M -1M
Ventes	16M 21M
Marge bénéficiaire	-4.943
Employés	81
EBITDA	14M -996K

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+80.72% upside

Dividendes
By Dow Jones
Prochains Résultats	5 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	316M 1B
Ouverture précédente	4.88
Clôture précédente	2.1

Sentiment de l'Actualité

By Acuity

95%

325 / 345 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

0.6863 / 0.72 Support & Résistance

Lexicon Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

18 mai 2026, 23:10 UTC

Actions en Tendance

Stocks to Watch: Agilysys, XP

18 mai 2026, 18:44 UTC

Principaux Mouvements du Marché

Claritev Shares Recover After Comments About DOJ

18 mai 2026, 23:55 UTC

Résultats

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 mai 2026, 23:37 UTC

Market Talk

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 mai 2026, 22:31 UTC

Acquisitions, Fusions, Rachats

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 mai 2026, 22:30 UTC

Acquisitions, Fusions, Rachats

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 mai 2026, 22:30 UTC

Acquisitions, Fusions, Rachats

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 mai 2026, 22:25 UTC

Acquisitions, Fusions, Rachats

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 mai 2026, 22:24 UTC

Acquisitions, Fusions, Rachats

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 mai 2026, 20:50 UTC

Market Talk

Acquisitions, Fusions, Rachats

Financial Services Roundup: Market Talk

18 mai 2026, 20:25 UTC

Résultats

Correct: XP 1Q Total Client Assets BRL1.53T

18 mai 2026, 20:23 UTC

Résultats

XP 1Q Total Client Assets BRL1.53B

18 mai 2026, 20:19 UTC

Résultats

XP 1Q Adj EPS BRL2.49 >XP

18 mai 2026, 20:19 UTC

Résultats

XP 1Q Rev BRL4.73B >XP

18 mai 2026, 19:10 UTC

Market Talk

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 mai 2026, 19:00 UTC

Résultats

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 mai 2026, 18:52 UTC

Market Talk

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 mai 2026, 18:17 UTC

Market Talk

Acquisitions, Fusions, Rachats

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 mai 2026, 17:22 UTC

Market Talk

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 mai 2026, 16:57 UTC

Acquisitions, Fusions, Rachats

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 mai 2026, 16:57 UTC

Market Talk

Global Energy Roundup: Market Talk

18 mai 2026, 16:57 UTC

Market Talk

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 mai 2026, 16:54 UTC

Acquisitions, Fusions, Rachats

Vinci Doesn't Set Out Financial Details of Deal

18 mai 2026, 16:50 UTC

Acquisitions, Fusions, Rachats

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 mai 2026, 16:49 UTC

Acquisitions, Fusions, Rachats

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 mai 2026, 16:49 UTC

Acquisitions, Fusions, Rachats

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 mai 2026, 16:48 UTC

Acquisitions, Fusions, Rachats

Vinci Buys Canada's Modern Group of Companies

Comparaison

Variation de prix

Lexicon Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

80.72% hausse

Prévisions sur 12 Mois

Moyen 4.03 USD 80.72%

Haut 6 USD

Bas 1 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

Achat

Maintien

Vente

Basé sur 4 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

0.6863 / 0.72Support & Résistance

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

325 / 345Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.